Cholesterol lowering for secondary prevention: what statin dose should we use? - sprookjes - yvandenbroek - TriplyDB

Cholesterol lowering for secondary prevention: what statin dose should we use?

Cholesterol lowering for secondary prevention: what statin dose should we use?

http://www.wikidata.org/entity/Q36536175

about

Cholesterol lowering for secondary prevention: what statin dose should we use?

http://www.wikidata.org/entity/Q36536175

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Cholesterol lowering for secondary prevention: what statin dose should we use?

@ast

Cholesterol lowering for secondary prevention: what statin dose should we use?

@en

type

label

Cholesterol lowering for secondary prevention: what statin dose should we use?

@ast

Cholesterol lowering for secondary prevention: what statin dose should we use?

@en

prefLabel

Cholesterol lowering for secondary prevention: what statin dose should we use?

@ast

Cholesterol lowering for secondary prevention: what statin dose should we use?

@en

P1433

Q36536175-572BE6DD-D8A1-4DA0-AEEB-9BB6EAEF6548

P1476

Q36536175-8993FFD1-C899-47E8-BFE3-65474E6F675E

P2093

Q36536175-0D771645-109A-4956-9677-54868F4CB46F

Q36536175-A8423C9B-2B53-4899-A296-6ACC2C891D5A

P2860

Q36536175-047FEE93-C135-47CE-9ABB-BDF52697E825

Q36536175-0B1FEDAC-AEFD-4CF2-A33B-5CA5F9B168E6

Q36536175-11AC7022-C162-4994-BCF9-AFB6B40E4634

Q36536175-1695E80B-15E3-4D0C-AD68-C379F1C162B6

Q36536175-17AF75A6-C0A1-41FB-926C-087FCC82B0C9

Q36536175-1D32357F-D315-44C1-8757-98495F6223A0

Q36536175-291530BA-F03A-4DC0-A0A9-EE31FEC73532

Q36536175-2B45AFA7-9A67-44A5-8793-93DDF5F937D3

Q36536175-2E615C66-1B00-4BDC-B63A-50FE14F76C75

Q36536175-39B5107E-30DD-49EC-9CD3-7EDC44DE0C9F

P304

Q36536175-026CD6FF-374F-4C9E-929E-6882D00DEF76

P31

Q36536175-BCBCFD46-DE8E-4C9F-9948-538D1C7FD3ED

P407

Q36536175-D951B531-5587-403C-B44C-11E04EEE7218

P433

Q36536175-4ED0D576-8941-4CC9-8898-B0C16941D94D

P478

Q36536175-19457FF2-7942-453A-9AAF-D01F2314B0B3

P577

Q36536175-520E1FD7-EB9F-427F-B875-7A49A8D8787C

P698

Q36536175-DD99F125-7A34-4EB8-AAAB-F592FF3854C6

P921

Q36536175-3E93FE36-DAEF-4909-BD27-8F71359A1C4C

Q36536175-A95EA9D8-DCCC-4835-AA2E-3CF8E5EE1683

Q36536175-F4E9978B-CCF7-44AA-9230-F00D90E5938F

P932

Q36536175-1590C9C0-B787-4ED3-92CD-28C8077CC080

P1433

Vascular Health and Risk Management

P1476

Cholesterol lowering for secondary prevention: what statin dose should we use?

@en

P2093

Finlay A McAlister

http://www.w3.org/2001/XMLSchema#string

Kiranbir Josan

http://www.w3.org/2001/XMLSchema#string

P2860

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

P304

615-627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18078013

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

polycyclic compound

P932

2291306

http://www.w3.org/2001/XMLSchema#string